Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose

2016 ◽  
Vol 16 (23) ◽  
pp. 2625-2633 ◽  
Author(s):  
Rajeev Kumar Singla ◽  
Radha Singh ◽  
Ashok Kumar Dubey
Keyword(s):  
Antidiabetic Drug

Ligand-fishing and bioactivity-correlated metabolomics for accelerated discovery of antidiabetic drug leads

Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
NT Nyberg ◽  
SG Wubshet ◽  
KT Kongstad ◽  
D Staerk
Keyword(s):  
Antidiabetic Drug ◽  
Ligand Fishing ◽  
Drug Leads

scholarly journals Ecological HPLC method for analyzing an antidiabetic drug in real rat plasma samples and studying the effects of concurrently administered fenugreek extract on its pharmacokinetics

RSC Advances ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 4740-4750
Author(s):  
Nada S. Abdelwahab ◽  
Amani Morsi ◽  
Yasmine M. Ahmed ◽  
Hossam M. Hassan ◽  
Asmaa M. AboulMagd
Keyword(s):  
Rat Plasma ◽  
Hplc Method ◽  
Diabetes Control ◽  
Plasma Samples ◽  
Antidiabetic Drug

The combination of fenugreek extract and metformin can be considered as an auspicious treatment for satisfactory diabetes control and minimizing the expected long-term complications of metformin.

scholarly journals Interaction of clozapine with metformin in a schizophrenia rat model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
G. Horvath ◽  
G. Kis ◽  
G. Kekesi ◽  
A. Büki ◽  
L. G. Adlan ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cognitive Function ◽  
Negative Symptoms ◽  
Antipsychotic Drugs ◽  
D1 Receptor ◽  
Antidiabetic Drug ◽  
Beneficial Effects ◽  
Adjuvant Therapies ◽  
Behavioral Parameters ◽  
The Brain

AbstractThe low efficacy of antipsychotic drugs (e.g., clozapine) for negative symptoms and cognitive impairment has led to the introduction of adjuvant therapies. Because previous data suggest the procognitive potential of the antidiabetic drug metformin, this study aimed to assess the effects of chronic clozapine and metformin oral administration (alone and in combination) on locomotor and exploratory activities and cognitive function in a reward-based test in control and a schizophrenia-like animal model (Wisket rats). As impaired dopamine D1 receptor (D1R) function might play a role in the cognitive dysfunctions observed in patients with schizophrenia, the second goal of this study was to determine the brain-region-specific D1R-mediated signaling, ligand binding, and mRNA expression. None of the treatments affected the behavior of the control animals significantly; however, the combination treatment enhanced D1R binding and activation in the cerebral cortex. The Wisket rats exhibited impaired motivation, attention, and cognitive function, as well as a lower level of cortical D1R binding, signaling, and gene expression. Clozapine caused further deterioration of the behavioral parameters, without a significant effect on the D1R system. Metformin blunted the clozapine-induced impairments, and, similarly to that observed in the control animals, increased the functional activity of D1R. This study highlights the beneficial effects of metformin (at the behavioral and cellular levels) in blunting clozapine-induced adverse effects.

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

2011 ◽  
Vol 50 (4) ◽  
pp. 569-577 ◽  
Author(s):  
E. Raschi ◽  
C. Piccinni ◽  
E. Poluzzi ◽  
G. Marchesini ◽  
F. De Ponti
Keyword(s):  
Drug Use ◽  
Antidiabetic Drug ◽  
Pharmacovigilance Database ◽  
Gaining Insight

scholarly journals Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e025806 ◽  
Author(s):  
Rimei Nishimura ◽  
Haruka Kato ◽  
Koichi Kisanuki ◽  
Akinori Oh ◽  
Shinzo Hiroi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Class ◽  
Japanese Patients ◽  
Medical Data ◽  
Treatment Patterns ◽  
Administrative Claims ◽  
Antidiabetic Drug

ObjectiveTo determine real-world trends in antidiabetic drug use, and persistence and adherence, in Japanese patients with type 2 diabetes mellitus (T2DM).DesignRetrospective evaluation of administrative claims data (2011–2015) using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases.SettingAnalysis of two administrative claims databases for Japanese patients with T2DM.ParticipantsAdults (aged ≥18 years) with an International Classification of Diseases, 10th Revision code of T2DM and at least one antidiabetic drug prescription.Main outcome measuresTreatment patterns in untreated (UT) or previously treated (PT) patients receiving antidiabetic therapy; persistence with treatment at 12 months; adherence to treatment at 12 months.Results40 908 and 90 421 patients were included from the JMDC and MDV databases, respectively. The most frequently prescribed therapy at the index (first prescription) date was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT patients (JMDC: 44.0%, MDV: 54.8%) and combination therapy in PT patients (74.6%, 81.1%). Most common combinations were DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT patients from either database whose index prescription was for any antidiabetic drug class(es) other than DPP-4i, the most frequent add-on or switch was to DPP-4i. 12-month persistence with index monotherapy was highest with DPP-4i and BG. Adherence was high (≥80%) for all monotherapy schedules, except insulin and glucagon-like peptide-1 agonist, and for the five most frequent two-drug and three-drug combinations. Persistence was greater in elderly UT patients and in those receiving ≤5 medications, but comparatively worse in UT patients with ≥3 index antidiabetic drug classes.ConclusionsThe findings indicate that DPP-4i is the most commonly used antidiabetic drug class in Japanese patients with T2DM, and persistence and adherence to this antidiabetic drug class are high.

scholarly journals Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility

2016 ◽  
Vol 2016 ◽  
pp. 1-14 ◽  
Author(s):  
Omolola R. Oyenihi ◽  
Ayodeji B. Oyenihi ◽  
Anne A. Adeyanju ◽  
Oluwafemi O. Oguntibeju
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Utility ◽  
Therapeutic Agent ◽  
Molecular Targets ◽  
Therapeutic Agents ◽  
Mechanisms Of Action ◽  
Antidiabetic Drug ◽  
Near Future ◽  
Antidiabetic Effects ◽  
The Way

Despite recent advances in the understanding and management ofdiabetes mellitus, the prevalence of the disease is increasing unabatedly with resulting disabling and life-reducing consequences to the global human population. The limitations and side effects associated with current antidiabetic therapies have necessitated the search for novel therapeutic agents. Due to the multipathogenicity ofdiabetes mellitus,plant-derived compounds with proven multiple pharmacological actions have been postulated to “hold the key” in the search for an affordable, efficacious, and safer therapeutic agent in the treatment of the disease and associated complications. Resveratrol, a phytoalexin present in few plant species, has demonstrated beneficial antidiabetic effects in animals and humans through diverse mechanisms and multiple molecular targets. However, despite the enthusiasm and widespread successes achieved with the use of resveratrol in animal models ofdiabetes mellitus, there are extremely limited clinical data to confirm the antidiabetic qualities of resveratrol. This review presents an update on the mechanisms of action and protection of resveratrol indiabetes mellitus, highlights challenges in its clinical utility, and suggests the way forward in translating the promising preclinical data to a possible antidiabetic drug in the near future.

scholarly journals Antihyperglycaemic therapies and cancer risk

2014 ◽  
Vol 11 (6) ◽  
pp. 371-389 ◽  
Author(s):  
Stefan Z Lutz ◽  
Harald Staiger ◽  
Andreas Fritsche ◽  
Hans-Ulrich Häring
Keyword(s):  
Cancer Risk ◽  
Large Scale ◽  
Tumour Growth ◽  
Molecular Mechanisms ◽  
Growth Promotion ◽  
Protective Effects ◽  
Antidiabetic Drug ◽  
Safety Issues ◽  
Drug Classes ◽  
Few Data

Aims: This review is aimed at highlighting the potential mitogenic/tumour growth–promoting or antimitogenic/tumour growth–inhibiting effects of the main antihyperglycaemic drug classes. Methods: We review and discuss the most current studies evaluating the association between antidiabetic medications used in clinical practice and malignancies as described so far. Results: Metformin seems to be the only antidiabetic drug to exert protective effects both on monotherapy and also when combined with other oral antidiabetic drugs or insulins in several site-specific cancers. In contrast, several other drug classes may increase cancer risk. Some reason for concern remains regarding sulphonylureas and also the incretin-based therapies regarding pancreas and thyroid cancers and the sodium glucose cotransporter-2 inhibitors as well as pioglitazone regarding bladder cancer. The majority of meta-analyses suggest that there is no evidence for a causal relationship between insulin glargine and elevated cancer risk, although the studies have been controversially discussed. For α-glucosidase inhibitors and glinides, neutral or only few data upon cancer risk exist. Conclusion: Although the molecular mechanisms are not fully understood, a potential risk of mitogenicity and tumour growth promotion cannot be excluded in case of several antidiabetic drug classes. However, more large-scale, randomized, well-designed clinical studies with especially long follow-up time periods are needed to get reliable answers to these safety issues.

Sign in / Sign up

Export Citation Format

Share Document